Pharma Journalist -

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for magrolimab, a first-in-class, investigational anti-CD47…
Read More...

University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is…
Read More...

Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ and Lonza announced a strategic collaboration…
Read More...

CuraSen Therapeutics, Inc., a privately held clinical-stage biotechnology company, announced that it has dosed its first subjects in a multi-part, Phase 1 clinical study with CST-2032,…
Read More...

Novus Therapeutics, Inc. announced it has completed the acquisition of Anelixis Therapeutics, Inc. a privately held clinical stage biotechnology company developing a next generation…
Read More...

BioNTech SE announced that it will receive a grant of up to 375 million Euro from an initiative by the German Federal Ministry of Education and Research (BMBF) to support the…
Read More...

Axovant Gene Therapies Ltd announced that it has signed a strategic partnership with Viralgen, a leading Contract Development and Manufacturing Organization (CDMO). Leveraging the…
Read More...

Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in…
Read More...

HiFiBiO Therapeutics, a clinical-stage multinational biotherapeutics company focused on the development of novel antibodies in immunomodulation, announced a partnership agreement with…
Read More...

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in a phase 2 study evaluating patritumab deruxtecan (U3-1402), a HER3…
Read More...